News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
|
Followers
|
14
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
53
|
|
Created
|
10/31/08
|
Type
|
Free
|
| Moderators | |||
U.S NeuroSurgical, Inc. (USN) is a medical services company that partners with hospitals and physicians to own and operate facilities utilizing state-of-the-art and innovative technologies in medical treatment and/or diagnosis. USN takes the financial risk for the facility and participates with local partners in promoting the success of the project
USN owns and operates Gamma Knife centers and has been doing so for over a decade. In our twenty five year history in the health care business, we have successfully developed ventures in medical software, capitated specialty networks, managed care, web-based pharmacy, reproductive endocrinology systems, women's wellness centers and substance abuse treatment centers.
USN continues to grow its business by working with our current partners and adding new ones to bring together our collective goals and make them real. Our expertise is in finance, market analysis and project development. We are a financially strong, seasoned group of investors, operators and specialists. Our commitment is to excellence and integrity in an industry that demands these qualities.
The following list identifies services in which U.S. NeuroSurgical is pursuing opportunities.
The Gamma Knife, a remarkable, 20 ton medical device, was invented in 1968 by a Swedish duo, Dr. Lars Leksell of Karolinska Institute and biophysicist Professor Borje Larsson. Since then more than 150,000 patients worldwide have been treated with the Gamma Knife. Recent advances in neuro-imaging techniques and the increasing power of computers have been responsible for the rapid growth of radiosurgery in recent years. Many years of well-documented research and clinical evaluation support the efficacy of Gamma Knife technology.
Gamma Knife radiosurgery is not intended to replace conventional neurosurgery, but it is an effective, additional weapon to combat vascular malformations and tumors of the brain. Gamma Knife treatment may serve as an adjunct to standard neurosurgical therapy or as the preferred course of treatment when traditional surgery is not recommended.
Not really a knife at all, the Gamma Knife is a unique stereotactic radiosurgical device used to treat brain tumors and other malformations of the brain without invasive surgery. The Gamma Knife delivers a single, high dose of ionizing radiation emanating from 201 cobalt-60 sources positioned about a hemispherical, precision machined cavity. The lesion is first targeted with precise accuracy using advanced imaging and three dimensional treatment planning such as CT Scans or MR Scans. Each individual beam is focused on a common target, producing an intense concentration of radiation at the target site, destroying the lesion while spreading the entry radiation dose uniformly and harmlessly over the patient's skull. The mechanical precision at the target site is +/- 0.1mm (1/10 of 1 millimeter). Because of the steep fall-off in the radiation intensity surrounding the target, the lesion can be destroyed while sparing the surrounding tissue.
The Gamma Knife is superior to other stereotactic radiosurgery devices in its precision and its method of operation. The procedure, performed in a single treatment, sharply reduces hospital stay and eliminates the risk of post-surgical bleeding and infection that can be associated with conventional surgery. Most patients are able to leave the hospital within a few hours of their Gamma Knife treatment.
 |  |
 |  |
Scott Hamilton spoke about his personal experience with Gamma Knife surgery in an interview with Katie Couric on NBC's "Today Show"
Watch Scott Hamilton on NBC's "Today Show" here: http://www.usneuro.com/gamma.htm
| U.S. NeuroSurgical, Inc. 2400 Research Blvd Suite 325 Rockville, MD 20850
|
|
|
AI
